Radioembolization for Hepatocellular Carcinoma

2021 ◽  
Author(s):  
Seyda Gunduz ◽  
Gia Saini ◽  
Nicole Segaran ◽  
Sailen Naidu ◽  
Indravadan Patel ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Option ◽  
Early Stage ◽  
Curative Treatment ◽  
Treatment Modalities ◽  
Bridge To Transplantation ◽  
Underlying Liver Disease ◽  
Image Guided ◽  
Advanced Stages

AbstractHepatocellular carcinoma (HCC) is the fastest-growing cancer worldwide, causing significant morbidity and mortality. Surgical resection, ablation, or transplantation is the best treatment option for patients with HCC. However, only about one-fifth of patients are suitable for such primary curative treatments due to underlying liver disease or rapid extension of the tumor. Image-guided locoregional therapies may prove an important alternative in this scenario, particularly transarterial radioembolization (TARE) with yttrium-90 (Y-90). Based on many studies, TARE can be considered a curative treatment option for patients with early-stage HCC, a bridge to transplantation, and a method for downstaging tumors to give patients with unresectable HCC a chance to potentially receive a curative treatment. TARE can be also combined with other treatment modalities to provide a better quality of life in patients when compared with systemic therapy in patients with unresectable HCC. Here, we discuss the use of TARE in the approach to HCC patients who are in early, intermediate, or advanced stages.

Racial/Ethnic Disparities in Early-Stage Hepatocellular Carcinoma Curative Treatment Rates Within Asian and Hispanics in Los Angeles

2017 ◽  
Vol 152 (5) ◽  
pp. S1197
Author(s):  
Chiranjeevi Gadiparthi ◽  
Rosann Cholankeril ◽  
Eddie L. Copelin ◽  
Mairin Joseph-Talreja ◽  
Muhammad Ali Khan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Los Angeles ◽  
Early Stage ◽  
Ethnic Disparities ◽  
Curative Treatment ◽  
Racial Ethnic

Management of Advanced and Terminal Hepatocellular Carcinoma: When and How to Treat, and When not to Treat?

2017 ◽  
Vol 01 (02) ◽  
pp. 138-144
Author(s):  
William Rilling ◽  
Sarah White
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Median Overall Survival ◽  
Performance Status ◽  
Hepatic Function ◽  
Tumor Characteristics ◽  
Underlying Liver Disease ◽  
Advanced Hcc ◽  
The Third

AbstractHepatocellular carcinoma (HCC) is the third leading cause of cancer worldwide according to the National Cancer Institute. If treated with liver directed therapy, patients' median overall survival is significantly improved at 20.1 versus 4.3 months without treatment. The purpose of this article is to give an overview on when and how to treat, and when not to treat patients with advanced or terminal HCC. Treatment of patients with advanced HCC can be challenging, as patients are often already debilitated due to their chronic underlying liver disease. Performance status, hepatic function, tumor characteristics, and the patient's desire to maintain their quality of life should be at the forefront of deciding when and how to treat this patient population. If patients are found to be outside treatment criteria, referral to palliative care can be beneficial.

Early-Stage Hepatocellular Carcinoma in Patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency Ablation

Radiology ◽  
2005 ◽  
Vol 234 (3) ◽  
pp. 961-967 ◽  
Author(s):  
Riccardo Lencioni ◽  
Dania Cioni ◽  
Laura Crocetti ◽  
Chiara Franchini ◽  
Clotilde Della Pina ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Early Stage ◽  
Long Term Results ◽  
Image Guided

scholarly journals Factors predicting long-term outcome of early stage hepatocellular carcinoma after primary curative treatment - the role of surgical or nonsurgical methods

2020 ◽  
Author(s):  
Ming-Jeng Kuo ◽  
Chi-Ling Chen ◽  
Lein-ray Mo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Late Recurrence ◽  
Early Recurrence ◽  
Curative Treatment ◽  
Treatment Modalities ◽  
Long Term Outcome ◽  
Increased Risk ◽  
Significant Difference ◽  
Early Hcc ◽  
Time Varying Covariates

Abstract Background The effect of putative factors on the clinical course of early hepatocellular carcinoma (HCC) after primary surgical or nonsurgical curative treatment, which remains elusive, was quantified. Methods Patients with newly diagnosed early HCC who received surgical resection (SR) or percutaneous radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) from January 2003 to December 2016 were enrolled. The cumulative overall survival (OS) and disease-free survival (DFS) were compared. A polytomous logistic regression was used to estimate factors regarding early and late recurrence. Independent predictors of OS were identified using Cox proportional hazard regression. Results One hundred twenty-five patients underwent SR, and 176 patients underwent RFA, of whom 72 were treated with TACE followed by RFA. Either match analysis based on propensity score or multiple adjustment regression showed no significant difference in DFS and OS between the two groups. Multivariate analysis showed high AFP (>= 20 ng/mL), and multinodularity significantly increased risk of early recurrence (<=1year). In contrast, hepatitis B virus, hepatitis C virus and multinodularity were significantly associated with late recurrence (>1year). Multivariate Cox regression with recurrent events as time-varying covariates identified older age (HR=1.55, 95% CI:1.01-2.36), clinically significant portal hypertension (CSPH) (HR=1.97, 95% CI:1.26-3.08), early recurrence (HR=6.62, 95% CI:3.79-11.6) and late recurrence (HR=3.75, 95% CI:1.99-7.08) as independent risk factors of mortality. A simple risk score showed fair calibration and discrimination in early HCC patients after primary curative treatment. In the Barcelona Clinic Liver Cancer (BCLC) stage A subgroup, SR significantly improved DFS comparing to those received RFA with or without TACE. Conclusion Host and tumor factors rather than the initial treatment modalities determine the outcomes of early HCC after primary curative treatment. Statistical models based on recurrence types can predict early HCC prognosis but further external validation is necessary.

scholarly journals Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

HPB Surgery ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Saleem Ahmed ◽  
Nurun Nisa de Souza ◽  
Wang Qiao ◽  
Meidai Kasai ◽  
Low Jee Keem ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Palliative Therapy ◽  
Advanced Stages ◽  
The Impact

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment for unresectable HCC. It is however unclear if TACE improves the quality of life (QoL) in patients with HCC. The aim of this review is to evaluate the impact of TACE on QoL of HCC patients.

scholarly journals CHEMOTHERAPY AND HORMONE THERAPY FOR BREAST CANCER AND COMPLICATIONS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Seema Devi ◽  
Yogesh Kumar Sharma
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Hormone Therapy ◽  
Chemotherapeutic Agents ◽  
Treatment Modalities ◽  
Mental Function ◽  
Advanced Stages ◽  
Cardiovascular Functions ◽  
Chemotherapy Adjuvant

Breast cancer is second leading cause of death in women. Treatment modalities for breast cancer optimized according to stage at which the cancer is diagnosed. Chemotherapy, hormone therapy   and targeted therapies are used for the treatment of advanced stages of disease. The aim of therapy different like to enhancing the curative rate in adjuvant therapy, reduce symptoms or  improve quality of life in metastatic diseases, reduce the chances of the cancer coming Back. The complications of therapy including mental function; cardiovascular functions; neuromusculoskeletal and movement related functions and structures functions of hematological immunological and respiratory system etc. The benefits of chemotherapy are limited and relative compared to the risk factors. Chemotherapeutic agents use in treatment of breast cancer such as taxanes (docetaxel and paclitaxel), tamoxifen , vincristine, cyclophosphamide, trastuzumab etc. Keyword: breast cancer, hormone therapy, targeted therapy, chemotherapy, adjuvant therapy.

Sign in / Sign up

Export Citation Format

Share Document